Strategic Partnership A collaboration with Daiichi Sankyo validates Wayfinder's RNA targeting platform and creates strong opportunities to pursue additional co development or licensing deals with large pharma in neurodegenerative and oncology spaces.

Platform Differentiator Wayfinder combines screening and computational methods to rapidly discover potent and selective RNA targeting small molecules, enabling a compelling offering for pharma and biotech clients seeking to unlock historically undruggable RNA targets.

Neuro Oncology Focus The emphasis on oncology and neurodegeneration aligns with growing interest in RNA based therapies and provides a clear pathway to expand the pipeline through shared research and development collaborations.

Lean Growth Engine A compact operating model with seed level funding and early revenue signals capital efficiency and the ability to execute agilely on collaborative programs without a large corporate overhead.

Seattle Advantage Based in Seattle with founders from the University of Washington, Wayfinder benefits from a strong scientific ecosystem to attract partners, talent, and translational partnerships to accelerate milestones.